BioTuesdays

Tag - TCON

Tracon Pharmaceuticals Logo

HCW halves Tracon Pharma PT to $6 from $13

H.C. Wainwright slashed its price target for Tracon Pharmaceuticals (NASDAQ:TCON) to $6 from $13, but reiterated its “buy” rating, after the company and partner, Santen Pharmaceutical, discontinued development of DE-122...

Tracon Pharmaceuticals Logo

HCW starts TRACON Pharma at buy; PT $2

H.C. Wainwright launched coverage of TRACON Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $2 price target. The stock closed at 57 cents on Aug. 29. TRACON is developing targeted therapeutics for cancer...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.